TELMISARTAN HCTZ 80 MG
TELMISARTAN : 80 MG HYDROCHLOROTHIAZIDE : 12.5 MG · DIN 02390302 · SIVEM PHARMACEUTICALS ULC
Health Canada status: MARKETED
What is TELMISARTAN HCTZ?
TELMISARTAN HCTZ 80 MG contains TELMISARTAN : 80 MG HYDROCHLOROTHIAZIDE : 12.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02390302, held by SIVEM PHARMACEUTICALS ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 14-Aug-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TELMISARTAN HCTZ used for?
Treatment of mild to moderate essential hypertension in patients for whom combination therapy is appropriate or not adequately controlled by monotherapy. Not for initial therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02390302 |
|---|---|
| Brand name | TELMISARTAN HCTZ |
| Generic / active ingredient | TELMISARTAN : 80 MG HYDROCHLOROTHIAZIDE : 12.5 MG |
| Manufacturer | SIVEM PHARMACEUTICALS ULC |
| Strength | 80 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C09DA07 TELMISARTAN AND DIURETICS |
| AHFS class | 24:32.08 ; 40:28.20 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 14-Aug-2025 |
| Original market date | 2012-07-26 00:00:00 |
How is it administered?
Once daily oral administration, swallowed whole with liquid, with or without food. Not for initial therapy. Titrate based on response to individual components.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (standard section 11 mentioned in TOC but text cuts off).
How is it supplied?
HDPE bottles of 100 tablets; blister-sealed cartons of 30 tablets (3 cards of 10).
Contraindications
Concomitant use with aliskiren in patients with diabetes or renal impairment; hypersensitivity to ingredients; pregnancy; breast-feeding; anuria; rare hereditary galactose intolerance.
Warnings and precautions
Fetal toxicity; risk of non-melanoma skin cancer; hypotension in volume-depleted patients; dual blockade of RAS; acute respiratory distress syndrome; angioedema; choroidal effusion.
Is TELMISARTAN AND DIURETICS in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SIVEM PHARMACEUTICALS ULC, last seen 13 May 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C09DA07 TELMISARTAN AND DIURETICS. 22 of 42 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-TELMISARTAN HCTZ | 80 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02419122 |
| ACH-TELMISARTAN HCTZ | 80 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02419114 |
| AG TELMISARTAN-HCT | 12.5 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02484560 |
| AG TELMISARTAN-HCT | 25 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02484579 |
| AURO-TELMISARTAN HCTZ | 25 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02456397 |
| AURO-TELMISARTAN HCTZ | 80 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02456389 |
| JAMP TELMISARTAN-HCT | 12.5 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02389940 |
| JAMP TELMISARTAN-HCT | 80 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02389959 |
| MICARDIS PLUS | 25 MG | TABLET | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | MARKETED | DIN 02318709 |
| MICARDIS PLUS | 80 MG | TABLET | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | MARKETED | DIN 02244344 |
Who else supplies TELMISARTAN AND DIURETICS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TELMISARTAN AND DIURETICS appears in 482 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.